Find clinical trials

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome.  Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Chronic, non-healing foot and leg ulcers are often a result of reduced blood flow due to Peripheral Artery Disease (PAD) or other ischemic (reduced blood flow) conditions in patients with chronic diseases, such as diabetes. These ulcers can compromise quality of life and increase the risk of serious infection and result in injury and death of the tissue. The XPD is a new device that is designed to stretch the soft tissue around the bone (called the periosteum) to trigger the body’s natural healing process. It moves in a slow, controlled way to support healing and new tissue growth.